BioSpace News Archive

The global market for bacteriophage market is expected to rise at an exponential rate during the forecast period owing to its crucial role in molecular and genetics biology.

Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021

Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian patients and physicians which validated the primary endpoint of the SERENITY © pivotal trial. The results confirm that the primary endpoint in the SERENITY © clinical trial is accurate About Cancer Cachexia Fifty to 80% of cancer

March 26, 2020 11:00 UTC Karuna Therapeutics to Participate in Stifel’s 2 nd Annual CNS Day Virtual Event BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna The

Somryst is the first FDA-authorized prescription digital therapeutic (PDT) for patients with chronic insomnia and the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program Somryst delivers digital Cognitive Behavioral Therapy for insomnia, including algorithm-driven sleep restriction and consolidation recommendations, and provides patients with treat

Dynavax to provide CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of COVID-19 vaccines

The Deputy Prime Minister will join ministers and Government of Canada officials to provide an update on COVID-19.

Company to hold investor conference call today, March 26, 2020 at 8:30 am ET –

Candida auris is another growing and serious infectious global health threat that particularly impacts healthcare settings. In the United States there were more than 1,000 clinical cases and 2,000 colonized patients reported by the CDC as of February 6, 2020

Aprea Therapeutics, Inc. , today reported financial results for the three months and year ended December 31, 2019 and provided a corporate update. Corporate Update: The Company is conducting, supporting and planning multiple clinical trials of APR-246: Pivotal Phase 3 MDS Trial— The